MAP2K7 and neoplasm: These results were further supported by a significant Calebin A-induced (100 mg/kg) tumor size reduction in a xenograft mouse model within two weeks (Table 2), regardless of whether Calebin A was administered alone or in combination with selumetinib (2 mg/kg), a MEK inhibitor (86).